Evidence

STEP-COUNT: STudy to Evaluate Physical and COgnitive functioning between patients with mUltiple myeloma who coNTinue or stop treatment with dara-Rd.

To compare physical activity, defined as the number of steps per day in months 4 to 6 after randomization, between patients who continue Dara-Rd versus patients who have a Treatment Free Interval (TFI).

N=150 Patients with newly diagnosed, non-transplant eligible multiple myeloma who have received 12 cycles of Dara-Rd and have at least a partial response, who are treated in the HOVON 174 study.

Start Q1 2026

The overall aim of this study is to identify and describe distinct recovery trajectories with the innovative digital resilience assessment tool (Orion) in older oncology patients and patients with stage IV lung cancer during systemic therapy.

N=120 The study population consists of patients with a solid tumour starting treatment with systemic therapy (chemotherapy, immunotherapy, tyrosine kinase inhibitors, or a combination). Within the TENT consortium, participants are ≥70 years old and have any solid tumour. Within Longkankernet, included patients have stage IV Lung cancer and are ≥60 years old.

Part of the Orion SaMD solution.

This study is funded by KWF

 To explore and develop an algorithm for detection and prediction of Freezing of Gait episodes using smartphones and pressure sensing insoles.

N= 30 Persons with Parkinson Disease, data collection in lab setting and at home. Collaboration with University of Twente and Radboud University.

Finished and transferred to sherpa.

This study is funded by (OP) ERDF East Netherlands.

In this study the primary aim is to evaluate the effectiveness, in terms of self-efficacy control and quality of life, and the cost-effectiveness of self-monitoring based management of MS through the use of the MS sherpa app compared to care as usual without MS sherpa.

N=225, 125 intervention group, 100 control group, collaboration with Amsterdam UMC, 3 STZ hospitals, MS4Research institute and the Radboud University.

Protocol approved by METC, recruitment ongoing.

This study is funded by Nationaal MS Fonds and NWO.

Develop and explore measuring methods using built-in sensors of conventional smartphones and wearables to quantify fatigue, disease activity and progression in a day-to-day setting in patients with MS.

N=125, 100 persons with MS, 25 healthy controls, collaboration with Amsterdam UMC, last patient visited in February 2021.

In data analysis phase, scientific publications in preparation.

The aim of this study is to assess the validity, sensitivity and ease of use of new mobile self-monitoring tools for people with Relapsing-Remitting Multiple Sclerosis.

N= 25 MS patients, N= 79 healthy controls.

Completed.